Medical Condition News

RSS

Heart Institute's first LHIN program in Ontario for emergency heart attacks

Heart attack victims who live outside Ottawa's urban centre now are part of the University of Ottawa Heart Institute's (UOHI) far-reaching emergency life-saving program, ensuring urgent standardized treatment regardless of geography and, for the first time in Ontario, throughout an entire regional health district.

18 Sep 2009

Researchers to focus on abnormal fetal growth and chronic kidney disease

The National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $3.5 million to study epigenetic changes - chemical modifications of genes caused by stress, diet or other environmental influences - and how they contribute to human diseases and biological processes.

18 Sep 2009

$650 million funding from HHS to benefit black and Latino communities

The health of the nation's black and Latino communities stands to get a significant shot in the arm from the $650 million in health and wellness funding announced this afternoon by the Department of Health and Human Services, according to PolicyLink, a national research and advocacy organization.

18 Sep 2009

Study compares annual healthcare costs of diabetic and non-diabetic individuals

Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Sep 2009

Diabetic nerve pain: Most bothersome complication of diabetes

In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition's impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49 percent) were treating their pain.

18 Sep 2009

Griffin Securities' report features stem cell hypothesis of cancer

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by Griffin Securities, a New York-based brokerage firm, highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

Drug carrier that cuts off blood supply to tumors

To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.

18 Sep 2009

Mayo Clinic scientists conduct clinical study on functional dyspesia patients

"Nerve cells are found throughout the body, and just as their dysfunction in the brain can cause depression, we suspect overly sensitive nerves in the gut can produce this very uncomfortable indigestion," says Nicholas Talley, M.D., Ph.D., chair of the trial and chair of the Department of Internal Medicine at the Mayo Clinic campus in Florida.

18 Sep 2009

Treatment is the best way for problem gamblers, says gambling addiction expert

A leading expert on gambling addictions, saying that "prohibition doesn't work," today praised the Illinois Video Gaming Act for addressing the issue head-on by providing funding for treatment programs.

18 Sep 2009

Early detection of Alzheimer's can prevent disease progression

More than 5.3 million Americans are living with Alzheimer's, and every 71 seconds someone in America develops the disease.

18 Sep 2009

AFA welcomes inclusion of cognitive impairment screening in healthcare reform proposal

The Alzheimer's Foundation of America (AFA) today applauded Senate Finance Committee Chairman Max Baucus (D-MT) and Senator Tom Carper (D-DE), who spearheaded the provision, for including cognitive impairment screening for Medicare beneficiaries in Baucus' healthcare reform proposal, "America's Healthy Future Act of 2009."

18 Sep 2009

PSC activation mechanisms help develop novel therapeutic approaches for pancreatic fibrosis

Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour. Pancreatic stellate cells (PSC) are the principal effector cells in pancreatic fibrosis. They are activated by profibrogenic mediators, which include, for example, cytokines and ethanol metabolites.

18 Sep 2009

Deterioration in brain function following breast cancer therapy has negative effects on quality of life

One of the most problematic side effects of cancer treatment, chemobrain - a range of symptoms including memory loss, inability to concentrate, difficulty thinking and other subtle cognitive changes following chemotherapy - seriously diminishes women's quality of life and daily functioning.

18 Sep 2009

African Americans at higher risk of developing potentially deadly DVT and PE than other ethnic populations

Speaking at the Venous Disease Coalition (VDC) Annual Meeting today, Dr. Garth Graham from the Office of Minority Health at the Department of Health and Human Services followed up on last year's Surgeon General's Call to Action by focusing attention on the African American population which is at significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

18 Sep 2009

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.

17 Sep 2009

CCPHA research reveals the serious health risks of drinking soda

While health officials have long suspected the link between obesity and soda consumption, research released today provides the first scientific evidence of the potent role soda and other sugar-sweetened beverages play in fueling California’s expanding girth.

17 Sep 2009

InterMune and National Jewish Health to collaborate in the research of idiopathic pulmonary fibrosis

InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

17 Sep 2009

Essilor announces first-ever eco-friendly eyewear

Back to school is an important time for families and eyesight, as many schools require eye exams and teachers notice vision needs through classroom activities. With the start of a new school year, it's also a chance for families to kick start a new routine to support the environment and establish every day green habits.

17 Sep 2009

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide.

17 Sep 2009